Researchers discovered a gene that might be a key factor in the progression of Huntington’s disease in organoids. The gene may contribute to brain abnormalities much earlier than previously thought.
A recent survey of more than 8,000 patients found that users overwhelmingly supported receiving their test results immediately, even if their provider had not yet reviewed them.
A sensor identifies misfolded protein biomarkers in the blood. This offers a chance to detect Alzheimer's disease before any symptoms occur. Researchers intend to bring it to market maturity.
A DNA test has been shown to identify a range of hard-to-diagnose neurological and neuromuscular genetic diseases quicker and more-accurately than existing tests.
A new mechanism that stops the progression of Huntington’s disease in cells has been identified by scientists at the University of Cambridge and University College London (UCL), as part of their research groups at the UK Dementia Research Institute. Researchers say the breakthrough study, published in Cell Reports, could lead to much needed therapies for the rare genetic disease, which is…
Roche announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen (previously IONIS-HTTRx and RG6042) in manifest Huntington’s disease (HD). The decision was based on the results of a pre-planned review of the data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). The iDMC made its recommendation based on the…
A new idea for treating Alzheimer’s disease could eradicate the toxic proteins most closely linked to cognitive decline in the places where they do the most damage, a study from researchers at Columbia University Vagelos College of Physicians and Surgeons suggests. The study was published online in Science Translational Medicine.
A new low-cost method targeting genetic mutations often missed by existing diagnostic approaches has been developed. Researchers at Virginia Commonwealth University (VCU) in the United States noted that most rearrangement mutations implicated in cancer and neurological diseases fall between what can be detected by DNA sequence reads and optical microscopy methods. The new technique combines…
Scientists at St George’s, University of London, in collaboration with researchers from Germany, the USA, Tunisia and Iran have identified a new gene associated with the neuromuscular disorder, hereditary spastic paraplegia (HSP). The study, published in Nature Communications, also highlights a potential mechanism for the disease, which is already being targeted in drug trials for Alzheimer’s…
For the first time, scientists have found a way that can effectively transport medication into the brain - which could lead to improved treatments for neurological and neurodegenerative diseases. In a study, scientists from Newcastle University have led an international team in a major breakthrough in unlocking the secrets of how medications can infiltrate the brain.
A protein complex has been shown to play a key role in preventing the build-up of toxic plaques in the brain linked to neurodegenerative disorders such as Alzheimer’s and Huntington’s disease. An international team of researchers from the Universities of Leeds, Stanford (USA) and Konstanz (Germany) have discovered that the nascent polypeptide-associated complex (NAC) helps to prevent the…
Alzheimer’s, Parkinson’s and Huntington’s disease may have more in common than their effects on the functions of the brain and spinal cord. And finding that common thread could lead to a treatment that could work for all three. A recent study by David Smith, associate professor of biochemistry in the West Virginia University School of Medicine, suggests that at the heart of all three…
What if one of the prime suspects behind Alzheimer’s disease was a case of mistaken identity? Amyloid plaques, sticky buildup that accumulates in and around neurons in the brain, have long been believed to be an indicator of neurodegenerative disease. Most clinical drug trials for Alzheimer’s disease treatment have failed, presumably because they target these plaques. But according to Raymond…
A common feature of neurodegenerative diseases are deposits of aggregated proteins in the patient's cells that cause damage to cellular functions. Scientists report that, even in normal cells, aberrant aggregation-prone proteins are continually produced due to partial failure of the respiratory system. Unless they are removed by degradation, aggregates accumulate preferentially in the…
Modifying a DNA sequence to alter a cell to cure a disorder, prevent a genetic disease being passed on to next generations, or to use genetic modification as a way to diagnose a virus: yes, these tasks are possible. The recently discovered CRISPR technique can do it all.
Despite their different triggers, the same molecular chain of events appears to be responsible for brain cell death from strokes, injuries and even such neurodegenerative diseases as Alzheimer's. Now, researchers at Johns Hopkins say they have pinpointed the protein at the end of that chain of events, one that delivers the fatal strike by carving up a cell's DNA. The find, they say, potentially…
When there is an accident or a house fire, we call the police or the fire services. A control room quickly coordinates emergency operations. The cells in our bodies also have helpers in a crisis; the heat-shock proteins. These are triggered in response to cellular stress, such as high temperature, UV radiation or cancer. Heat-shock proteins help other proteins maintain their functional structure…
Dartmouth researchers and their colleagues have carried out the first total syntheses of certain compounds involved in excessive cell death in leukemia.
Integrated PET/MRI systems will permit the simultaneous acquisition of molecular, functional and structural parameters. The combined strengths of PET (high sensitivity and specificity, but relatively low spatial resolution) and MRI (high resolution, but low sensitivity) is the most attractive feature of multimodal imaging with hybrid scanners. Their application could substantially contribute to…
In an interview with Daniela Zimmermann, Executive Director of European Hospital, Dr Mohammad Naraghi, Head of the Department of Business Development at Siemens Medical Solutions, discussed developments in moleculary medicine, biochips, preventive diagnostics and a comprehensive and integrated health system for the future.